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Abstract Bruton’s tyrosine kinase (Btk) is essential for B cell
development and B cell antigen receptor (BCR) function. Recent
studies have shown that Btk plays an important role in BCR-
mediated c-Jun NH2-terminal kinase (JNK) 1 activation;
however, the mechanism by which Btk participates in the
JNK1 response remains elusive. Here we show that the BCR-
mediated Rac1 activation is significantly inhibited by loss of Btk,
while this Rac1 activation is not affected by loss of phospholipase
C-Q2 (PLC-Q2). Since PLC-Q2 is also required for BCR-mediated
JNK1 response, our results suggest that Btk regulates Rac1
pathway as well as PLC-Q2 pathway, both of which contribute to
the BCR-mediated JNK1 response. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Antigen-mediated clustering of B cell antigen receptor
(BCR) induces complex cascades of biochemical events that
culminate in proliferation, di¡erentiation, or apoptosis. The
BCR utilizes sequential activation of at least three types of
cytoplasmic protein tyrosine kinases (PTKs), Src-PTK, Syk,
and Bruton’s tyrosine kinase (Btk), to regulate downstream
e¡ectors [1^3]. Critical downstream signaling events include
the activation of mitogen-activated protein kinase (MAPK)
family members, comprising extracellular signal-regulated ki-
nase (ERK), c-Jun NH2-terminal kinase (JNK), and p38
MAPK. Di¡erent patterns of activation of these MAPKs
may lead to di¡erential expression of genes, and thereby con-
trasting cellular phenotypes such as growth or apoptosis in B
cells [4^6].
As in mast cells in which Btk is essential for FcORI-medi-
ated JNK1 response [7], we have recently provided evidence
that Btk regulates the JNK1 response in BCR signaling con-
text [8]. Since this JNK1 response requires both Rac1 and
phospholipase C-Q2 (PLC-Q2) pathways [9], two models could
be put forward to account for the requirement of Btk in the
JNK1 response. In the ¢rst model, given the requirement for
Btk in the PLC-Q2 pathway, Btk acts on only PLC-Q2 path-
way, which in turn regulates the JNK1 response. In the sec-
ond model, both PLC-Q2 and Rac1 pathways lie downstream
of Btk, and thereby leading to activation of JNK1. Here we
show the decrease of BCR-induced Rac1 activation in Btk-
de¢cient B cells, suggesting that Btk utilizes both pathways
for JNK1 activation.
2. Materials and methods
2.1. Cells and antibodies
Chicken B cell line DT40 wild-type and its derived mutant cells
(Btk-, PLC-Q2-de¢cient cells, and Btk-de¢cient cells expressing Btk)
were previously described [10,11]. Human B cell lines, C1LCL from
the neonatal cord blood and NH-1 from the peripheral blood of an X-
linked agammaglobulinemia (XLA) patient in whom the Btk mutation
leading to Btk protein de¢ciency had been identi¢ed [12], were estab-
lished by infection with a mutant Epstein^Barr virus (EBV) lacking
EBV latent membrane protein 2 (LMP2) as described [13,14]. These
cell lines were maintained in RPMI 1640 medium containing 10%
heat-inactivated fetal bovine serum, penicillin and streptomycin. The
following antibodies were used: anti-chicken IgM mAb, M4 (W, U)
[15], F(abP)2 fragments of a goat anti-human IgM (W) Ab (Biosource
International, Camarillo, CA, USA), anti-human JNK1 mAb (Phar-
mingen, San Diego, CA, USA), and anti-human Rac1 mAb (Upstate
Biotechnology, Lake Placid, NY, USA).
2.2. Biochemical analyses
In vitro kinase assay of JNK1 was performed as described previ-
ously [9]. For a⁄nity precipitation assay using GST^CRIB (Cdc42/
Rac interactive binding domain [CRIB] of rat PAK1 [amino acid 1^
125] fused to glutathione S-transferase), bacterially expressed GST^
CRIB prebound glutathione-Sepharose beads (20 Wl packed beads, 40
Wg of protein) were prepared as described [16]. Cell lysates in lysis
bu¡er (25 mM HEPES [pH 7.3], 150 mM NaCl, 5 mM MgCl2, 0.5
mM EGTA, 20 mM L-glycerophosphate, 10 mM NaF, 2 mM sodium
vanadate, 0.5% Triton X-100, 4% glycerol, 5 mM DTT, 0.5 mM
PMSF and 5 Wg/ml each leupeptin and pepstatin) [16] were incubated
with the beads for 10 min at 4‡C. After one wash in the lysis bu¡er,
bound proteins were eluted with SDS^PAGE sample bu¡er and re-
solved on 12.5% SDS^PAGE and subjected to Western blotting using
anti-Rac1 mAb.
3. Results and discussion
Using DT40 chicken B cells, we have previously shown that
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BCR-mediated JNK1 activation is a downstream event of Btk
[8]. To evaluate whether this conclusion is applicable to other
species, we examined human B-cell lines from normal individ-
uals (C1LCL) and from XLA patients (NH-1). In order to
establish these cell lines, B cells were transformed with a mu-
tant EBV lacking LMP2 [13,14]. As shown in Fig. 1B, normal
B cells evoked JNK1 activation upon BCR ligation, while
XLA B cells failed to induce the JNK1 response despite the
same expression level of BCR to that of normal B cells (data
not shown).
We and others have demonstrated that Btk regulates PLC-
Q2 activation in BCR signaling [11,17,18]. Given the evidence
that BCR-mediated JNK1 response requires both PLC-Q2 and
Rac1 activation [9], these observations indicate that Btk reg-
ulates only PLC-Q2, leading to the JNK1 response, or that
both of these two pathways lie downstream of Btk. To dis-
tinguish between these possibilities, we studied directly the
amount of GTP-bound Rac1 in wild-type and Btk-de¢cient
DT40 cells. To measure Rac1 activity, we used an a⁄nity
assay to precipitate Rac1-GTP from cell lysates [16,19,20].
In this assay, a fragment of p65/p21-activated kinase
(p65PAK) including the CRIB, a Rac1 e¡ector that binds
with high a⁄nity to Rac1-GTP but not to Rac1-GDP, was
used to construct an a⁄nity matrix. Stimulation by BCR led
to a rapid and transient activation of Rac1 in wild-type DT40
cells, whereas this activation was signi¢cantly inhibited in Btk-
de¢cient DT40 cells (Fig. 2A,B). Transfection of Btk into Btk-
de¢cient DT40 cells restored Rac1 activation as well as JNK1
response upon BCR ligation (Fig. 1A and 2A,B), con¢rming
that these defects are due to Btk. Although the stimulation-
fold in normal human B cells was lower than that in wild-type
DT40 B cells, the BCR-mediated Rac1 activation was repro-
ducibly observed. In contrast to normal B cells, XLA B cells
failed to activate Rac1 (Fig. 2C). Together, these results in-
dicate that Rac1 activation is regulated by Btk in BCR signal-
ing context.
To determine whether Rac1 activation lies downstream or
in parallel to PLC-Q2 activation in BCR signaling context, we
determined Rac1 activation in PLC-Q2-de¢cient DT40 cells
[10]. As shown in Fig. 2A,B, Rac1 activation occurred nor-
mally even in the absence of PLC-Q2, indicating that Rac1 is
activated independently of PLC-Q2 activation.
Using wild-type and Btk-de¢cient B cells, we have found
that BCR cross-linking induces the activation of Rac1, which
is regulated by Btk. Although the involvement of Btk in Rac1
activation is clear, the residual Rac1 activation in Btk-de¢-
cient DT40 B cells implicates that other PTKs such as Syk,
in addition to Btk, may play a role in Rac1 activation; this
additional PTK may be capable of activating Rac1 to some
extent even in the absence of Btk in DT40 B cells.
One of the pathways regulated by Rac1 is the JNK1 signal-
Fig. 1. Inhibition of BCR-induced JNK1 activation in Btk-de¢cient
cells. A: Various DT40 cells (5U106/sample) were stimulated with
M4 (4 Wg/ml) for indicated times. JNK1 was immunoprecipitated
and the precipitates were divided. The half of them were used for
Western blot analysis using anti-JNK1 mAb (lower panel). The re-
maining half were used for kinase activity using GST^c-Jun as a
substrate. The kinase reaction products were resolved by 12.5%
SDS^PAGE and their phosphorylation was quanti¢ed by autora-
diography (upper panel). B: Human B cell lines, C1LCL and NH-1
(2U106/sample), were stimulated for indicated times with F(abP)2
fragments of a goat anti-human IgM (W) Ab (14 Wg/ml), lysed and
immunoprecipitated with anti-JNK1 mAb. JNK1 activity was as-
sessed as described in (A).
Fig. 2. BCR-induced Rac1 activation requires Btk, but not PLC-Q2.
Various DT40 cells and human B cells were stimulated as described
in the legend to Fig. 1. After stimulation, cell lysates were used for
the a⁄nity precipitation assay in the presence of GST^CRIB as de-
scribed in Section 2. Proteins bound to GST^CRIB and aliquots of
whole-cell lysates were separated on SDS^PAGE (12.5% gel) and
were analyzed by Western blotting using anti-Rac1 mAb. A: Repre-
sentative results of the three independent experiments in DT40 cells
are shown. B: Peak activation of Rac1 in DT40 cells (at 3 min) was
analyzed by densitometric quanti¢cation and expressed as fold in-
crease compared to activity at time 0 (mean þ S.E.M., n = 3). C:
Representative results of the three independent experiments in hu-
man B cells were shown. Simulation-fold at 3 min (mean þ S.E.M.,
n = 3) is 1.4 þ 0.13 in C1LCL cells and 0.95 þ 0.01 in NH-1 cells.
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ing pathway; indeed, a dominant-negative mutant of Rac1
abrogates the BCR-mediated JNK1 activation in DT40 B cells
[9]. Thus, it is likely that Btk-regulated Rac1 activation is one
critical event for inducing JNK1 response in B cells. The mo-
lecular link(s) between Btk and Rac1 still remains elusive.
Recent reports demonstrate that Vav has guanine nucleotide
exchange activity towards Rho-family G proteins such as
Rac1 and Cdc42 [21] and that this activity is dependent on
its tyrosine phosphorylation [22]. Moreover, our recent study
has revealed that BCR-mediated Rac1 activation is attenuated
by V50% in Vav3-de¢cient DT40 B cells [23]. Collectively,
one potential model is that Btk mediates tyrosine phosphor-
ylation of Vav family proteins, which in turn regulates Rac1
activation. However, BCR-induced tyrosine phosphorylation
of Vav3 as well as Vav2 occurred normally in Btk-de¢cient
DT40 B cells, judged by anti-phosphotyrosine mAb blotting
(data not shown). These results suggest that Btk may regulate
Rac1 independently of Vav families, although we cannot com-
pletely exclude the possibility that the small changes of Vav2/
Vav3 phosphorylation may have escaped our detection sys-
tem.
Di¡erential time course between Rac1 and JNK1 activation
(stimulation peaks; 3 min versus 10 min) could be explained
by the existence of two distinct GTPases which might be in-
volved in the initial phase and the sustained JNK1 activation,
respectively. Reminiscence of this type of regulation is nerve
growth factor-mediated ERK activation; the early phase of
the ERK activation is mediated by Ras, but sustained activa-
tion of this pathway is due to Rap1 [24]. Analogous to this
mechanism, Rac1 might be involved only in initiation of the
JNK1 pathway and an additional GTPase might be required
for sustaining this response. Since Rac1 is known to regulate
the cytoskeletal organization [25], the alternative possibility is
that this Rac1-mediated cytoskeletal organization, in addition
to regulating MEKKs, is required for BCR-mediated JNK1
response. This cytoskeletal organization may require a rela-
tively long time, explaining the time lag between Rac1 and
JNK1 activation.
Normal BCR-mediated Rac1 activation in the absence of
PLC-Q2, together with the evidence that PLC-Q2 is involved in
BCR-mediated JNK1 response, suggests that the PLC-Q2-de-
pendent signals, PKC and calcium signals are integrated
downstream or in parallel to Rac1, leading to JNK1 activa-
tion. Hence, our results strongly support the model that Btk-
dependent pathways bifurcate, such that PLC-Q2 and Rac1
signals are generated, leading to convergence on JNK1 re-
sponse in B cells.
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